Hybrydowe leki hipotensyjno-hipolipemizujące – opcja czy konieczność terapeutyczna? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2020
Słowa kluczowe:
nadciśnienie tętnicze, hipercholesterolemia, hybrydowy lek złożony
##plugins.themes.bootstrap3.article.main##
Abstrakt
Strategia redukcji globalnego ryzyka sercowo-naczyniowego polega na jednoczesnym obniżaniu ciśnienia tętniczego i stężenia cholesterolu frakcji LDL. Stanowi to szczególne uzasadnienie dla stosowania hybrydowych leków złożonych, zawierających w jednej tabletce zarówno lek hipotensyjny, jak i hipolipemizujący. Szczególnie cenne wydają się w tym kontekście połączenia obejmujące: atorwastatynę, perindopril i amlodypinę.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Barylski , M. (2020). Hybrydowe leki hipotensyjno-hipolipemizujące – opcja czy konieczność terapeutyczna?. Medycyna Faktów , 13(1(46), 8-15. https://doi.org/10.24292/01.MF.0120.1
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Zdrojewski T, Bandosz P, Rutkowski M et al. Rozpowszechnienie, wykrywanie i skuteczność leczenia nadciśnienia tętniczego w Polsce – wyniki badania NATPOL 2011. Nad Tętn. 2014; 18: 116-7.
2. Zdrojewski T, Solnica B, Cybulska B et al. Rozpowszechnienie zaburzeń lipidowych w Polsce. Wyniki badania NATPOL 2011. Kardiol Pol. 2016; 74(3): 213-23.
3. Thoenes M, Bramlage P, Zhong S et al. Hypertension control and cardiometabolic risk: a regional perspective. Cardiol Res Pract. 2012; 2012: 925046.
4. Czarnecka D, Stolarz-Skrzypek K, Bednarski A et al. Therapeutic strategies in poorly controlled hypertension in outpatient setting in Poland – POSTER study. Fol Cardiol. 2015; 10(4): 242-8.
5. Niklas A, Marcinkowska J, Kozela M et al. Blood pressure and cholesterol control in patients with hypertension and hypercholesterolemia: the results from the Polish multicenter national health survey WOBASZ II. Pol Arch Intern Med. 2019; 129(12): 864-73.
6. Jackson R, Lawes CM, Bennett DA et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet. 2005; 365(9457): 434-41.
7. Zdrojewski T, Jankowski P, Bandosz P et al. Nowa wersja systemu oceny ryzyka sercowo-naczyniowego i tablic SCORE dla populacji Polski. Kardiol Pol. 2015; 73(10): 958-61.
8. Williams B, Mancia G, Spiering W et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021-104.
9. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2019; 5(1): 1-84.
10. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004; 25(6): 484-91.
11. Kostis JB, Breazna A, Deedwania PC et al. Treating to New Targets Steering Committee and Investigators. The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. J Clin Hypertens (Greenwich). 2008; 10(5): 367-76.
12. Kotseva K, De Backer G, De Bacquer D et al. EUROASPIRE Investigators. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019; 26(8): 824-35.
13. Mach F, Baigent C, Catapano AL et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111-88.
14. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147-52.
15. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38): 2940-8.
16. Colantonio LD, Rosenson RS, Deng L et al. Adherence to Statin Therapy Among US Adults Between 2007 and 2014. J Am Heart Assoc. 2019; 8(1): e010376.
17. Wiśniowska B, Skowron A. Ocena przestrzegania zaleceń lekarskich w terapii hipercholesterolemii. Farm Przegl Nauk. 2009; 11: 42-7.
18. Rodriguez F, Maron DJ, Knowles JW et al. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019; 4(3): 206-13.
19. Dahlöf B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895-906.
20. Gupta A, Mackay J, Whitehouse A et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127-37.
21. Sever P, Dahlöf B, Poulter N et al. ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006; 27(24): 2982-8.
22. Sirenko Y, Radchenko G. PERSPECTIVA Study Group. Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/ Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. High Blood Press. Cardiovasc Prev. 2017; 24(1): 85-93.
23. Athyros VG, Mikhailidis DP, Papageorgiou AA et al. GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens. 2004; 18(11): 781-8.
2. Zdrojewski T, Solnica B, Cybulska B et al. Rozpowszechnienie zaburzeń lipidowych w Polsce. Wyniki badania NATPOL 2011. Kardiol Pol. 2016; 74(3): 213-23.
3. Thoenes M, Bramlage P, Zhong S et al. Hypertension control and cardiometabolic risk: a regional perspective. Cardiol Res Pract. 2012; 2012: 925046.
4. Czarnecka D, Stolarz-Skrzypek K, Bednarski A et al. Therapeutic strategies in poorly controlled hypertension in outpatient setting in Poland – POSTER study. Fol Cardiol. 2015; 10(4): 242-8.
5. Niklas A, Marcinkowska J, Kozela M et al. Blood pressure and cholesterol control in patients with hypertension and hypercholesterolemia: the results from the Polish multicenter national health survey WOBASZ II. Pol Arch Intern Med. 2019; 129(12): 864-73.
6. Jackson R, Lawes CM, Bennett DA et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet. 2005; 365(9457): 434-41.
7. Zdrojewski T, Jankowski P, Bandosz P et al. Nowa wersja systemu oceny ryzyka sercowo-naczyniowego i tablic SCORE dla populacji Polski. Kardiol Pol. 2015; 73(10): 958-61.
8. Williams B, Mancia G, Spiering W et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39: 3021-104.
9. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce 2019; 5(1): 1-84.
10. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J. 2004; 25(6): 484-91.
11. Kostis JB, Breazna A, Deedwania PC et al. Treating to New Targets Steering Committee and Investigators. The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study. J Clin Hypertens (Greenwich). 2008; 10(5): 367-76.
12. Kotseva K, De Backer G, De Bacquer D et al. EUROASPIRE Investigators. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019; 26(8): 824-35.
13. Mach F, Baigent C, Catapano AL et al. ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111-88.
14. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005; 165(10): 1147-52.
15. Chowdhury R, Khan H, Heydon E et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38): 2940-8.
16. Colantonio LD, Rosenson RS, Deng L et al. Adherence to Statin Therapy Among US Adults Between 2007 and 2014. J Am Heart Assoc. 2019; 8(1): e010376.
17. Wiśniowska B, Skowron A. Ocena przestrzegania zaleceń lekarskich w terapii hipercholesterolemii. Farm Przegl Nauk. 2009; 11: 42-7.
18. Rodriguez F, Maron DJ, Knowles JW et al. Association of Statin Adherence With Mortality in Patients With Atherosclerotic Cardiovascular Disease. JAMA Cardiol. 2019; 4(3): 206-13.
19. Dahlöf B, Sever PS, Poulter NR et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895-906.
20. Gupta A, Mackay J, Whitehouse A et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127-37.
21. Sever P, Dahlöf B, Poulter N et al. ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2006; 27(24): 2982-8.
22. Sirenko Y, Radchenko G. PERSPECTIVA Study Group. Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/ Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. High Blood Press. Cardiovasc Prev. 2017; 24(1): 85-93.
23. Athyros VG, Mikhailidis DP, Papageorgiou AA et al. GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens. 2004; 18(11): 781-8.